12/23/2023 0 Comments Xtocc trial![]() CX-2029 is being developed in partnership with AbbVie. Protease activation is tightly controlled in normal tissues but often poorly regulated in tumor tissues leading to abundant levels of activated proteases.ĬX-2029 is currently being evaluated in a multi-cohort Phase 2 dose expansion study as monotherapy in patients with squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal or gastroesophageal junction cancer, or diffuse large B-cell lymphoma. CX-2029 has a peptide-mask that is held in place by a protease-cleavable linker. If you are interested in learning more about this study including participating sites, please visit .ĬX-2029-001, a Phase 1/2 study, is now enrolling patients with esophageal, lung, head and neck cancers or lymphoma.ĬX-2029 is a conditionally activated antibody-drug conjugate (Probody® therapeutic) employing the MMAE payload and targeting CD71, also known as the transferrin receptor 1. Purpose: The purpose of this first-in-human study is to evaluate the antitumor activity and characterize the safety and pharmacokinetics profiles of praluzatamab ravtansine, as monotherapy and in combination with pacmilimab, in patients with HER2-non-amplified breast cancer. Praluzatamab ravtansine monotherapy or in combination with pacmilimab is currently being evaluated in a Phase 2 study in three parallel enrolling arms: as monotherapy in patients with either a) hormone receptor-positive, HER2-non-amplified breast cancer (Arm A), or b) triple-negative breast cancer (TNBC Arm B), and c) in combination with pacmilimab in patients with TNBC (Arm C). Protease activation is tightly controlled in normal tissues but often poorly regulated in tumor tissues leading to abundant levels of activated proteases. Each of the Probody therapeutics has a peptide-mask that is held in place by a protease-cleavable linker. Pacmilimab (CX-072) is an anti-PD-L1 conditionally activated antibody. Praluzatamab ravtansine (CX-2009) is a conditionally activated antibody-drug conjugate (Probody® therapeutic) employing the DM-4 payload and targeting CD166, also known as activated leukocyte cell adhesion molecule (ALCAM). CX-2009-002, a Phase 2 multi-arm study, is now enrolling patients with human epidermal growth factor receptor 2 (HER2)-non-amplified breast cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |